Development of a cytokine-modified allogeneic whole cell pancreatic cancer vaccine

Dan Laheru, Barbara Biedrzycki, Elizabeth M. Jaffee

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Management of patients with pancreatic cancer is a multidisciplinary approach that presents enormous challenges to the clinician. Overall 5-year survival for all patients remains <3%. Symptoms of early pancreas cancer are nonspecific. As such, only a fraction of patients are candidates for surgery. While surgical resection provides the only curative option, most patients will develop tumor recurrence and die of their disease. To date, the clinical benefits of chemotherapy and radiation therapy have been important but have led to modest improvements. Tumor vaccines have the potential to specifically target the needle of pancreas cancer cells amidst the haystack of normal tissue. The discovery of pancreas tumor-specific antigens and the subsequent ability to harness this technology has become an area of intense interest for tumor immunologists and clinicians alike. Without knowledge of specific antigen targets, the whole tumor cell represents the best source of immunizing antigens. This chapter will focus on the development of whole tumor cell vaccine strategies for pancreas cancer.

Original languageEnglish (US)
Title of host publicationPancreatic Cancer
Subtitle of host publicationMethods and Protocols
PublisherHumana Press Inc.
Pages175-203
Number of pages29
ISBN (Print)9781627032865
DOIs
StatePublished - 2013

Publication series

NameMethods in Molecular Biology
Volume980
ISSN (Print)1064-3745

Keywords

  • Genetically modified whole cell allogeneic vaccine
  • Immunotherapy
  • Pancreas cancer
  • Tumor antigens

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics

Fingerprint Dive into the research topics of 'Development of a cytokine-modified allogeneic whole cell pancreatic cancer vaccine'. Together they form a unique fingerprint.

Cite this